GlobeNewswire

Fortum Deploys DigitalRoute Technology to Enable Data Driven Services Supporting Energy Sector Transformation

Dela

European utility Fortum is driving digital transformation within the energy sector, together with DigitalRoute. Starting with a digital solution for energy trading, by deploying machine learning algorithms based on DigitalRoute's Data Optimization Platform, the companies are now taking the next steps in building data driven services within the energy sector.

STOCKHOLM, Sweden, Dec. 19, 2017 (GLOBE NEWSWIRE) -- DigitalRoute, the leading Data Integration and Data Management company, and key European energy provider, Fortum, have jointly announced the completion of a successful Proof of Concept project. Fortum is a leading clean-energy company offering electricity, heating and cooling solutions as well as driving the change for a cleaner world.

Fortum has been looking for an IoT enabling platform to develop data-driven solutions and has now chosen to partner with DigitalRoute. DigitalRoute's platform allows for real-time communication between assets, plants, data sources and business systems, resulting in optimal quality data, which can be utilized to simplify the deployment of new solutions and optimize key processes.

The recently completed Proof of Concept focused on optimizing two different operational processes, both highlighting the benefits of Data Quality; to secure high quality data and then apply machine learning in order to optimize trading decisions.

The Use Case showed how DigitalRoute's solution could be used to predict intraday prices on the Nordic Energy market using external and internal data. Direct integration between the DigitalRoute Data Optimization Platform and market data sources enabled this provider to gain increased operational control, speed and commercial agility.

Fortum's Vice President, Trading and Asset Optimization, Simon-Erik Ollus, observed: "In partnership with DigitalRoute, we can increase both our momentum in the market as well as our self-sufficiency. We can focus on simplifying the deployment of new solutions and optimizing business processes, enabling a fast time-to-market."

Fortum will now utilize the experiences from the Proof of Concept in other areas such as operation and maintenance optimization of charging infrastructure, Smart Living services and further solutions within energy trading.

DigitalRoute CEO Andreas Zartmann said: "Our technology is a game changer for cutting-edge utility providers and we are delighted that Fortum is working with us to demonstrate how energy companies can use it to turn innovations from an opportunity into a commercial success. We are also excited to partner with a visionary player in a fast-changing industry. Once again, this underlines the wide scope of challenges DigitalRoute's technology can address."

About DigitalRoute®

DigitalRoute has been providing new approaches to data integration and data management since 1999. Its technology offers high throughput and provides a unique degree of user configurability, processing all usage and statistical data extracted from networks of connected assets. This means customers gain greater cost efficiencies, improved time-to-market for new service offerings, the ability to monetize any data, and the means to enhance end-customer satisfaction. DigitalRoute makes network events available to the right systems in the right formats in the most appropriate volumes at the required times, without losing a single bit. This is the foundation from which multiple, mission-critical use-cases can be addressed.

Over 350 leading companies worldwide use DigitalRoute technology to meet their data management needs, including a number of OEM partners who use our platform as a central part of their own offerings. DigitalRoute is built on the core values of Expertise, Open-Mindedness and Commitment. With close to 200 employees, the company is headquartered in Stockholm, Sweden with regional offices in Gothenburg, Atlanta and Kuala Lumpur. DigitalRoute is a venture-backed, privately-held company.

For more information or interviews with Andreas Zartmann contact:

Sancha Brody, Media & Analyst Relations
Email: sancha.brody@digitalroute.com
Phone: +44 (0)7376 366855

https://www.facebook.com/DigitalRoute
https://twitter.com/digital_route
https://www.linkedin.com/company/36031?trk=tyah

DigitalRoute and MediationZone are registered trademarks of Digital Route AB. All other trademarks are the property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DigitalRoute via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum